WHWK

Whitehawk Therapeutics, Inc. Common Stock

1.70 USD
+0.00
0.00%
At close Apr 2, 4:00 PM EDT
After hours
1.68
-0.02
1.18%
1 day
0.00%
5 days
-11.46%
1 month
-26.09%
3 months
-45.86%
6 months
-13.27%
Year to date
-45.86%
1 year
-22.02%
5 years
218.11%
10 years
-56.41%
 

About: Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.

Employees: 53

0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

309% more call options, than puts

Call options by funds: $94K | Put options by funds: $23K

100% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]

91% more capital invested

Capital invested by funds: $24.7M [Q3] → $47.2M (+$22.5M) [Q4]

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

2% more funds holding

Funds holding: 52 [Q3] → 53 (+1) [Q4]

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

Research analyst outlook

We haven’t received any recent analyst ratings for WHWK.

Financial journalist opinion

Based on 3 articles about WHWK published over the past 30 days

Neutral
PRNewsWire
1 week ago
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
MORRISTOWN, N.J. , March 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced the successful closing of the divestiture of Aadi Subsidiary, Inc. ("Aadi Sub") to Kaken Pharmaceuticals ("Kaken") for a cash payment of $100 million plus certain customary adjustments, completing the strategic transformation first announced in December 2024.
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
Neutral
Seeking Alpha
2 weeks ago
Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript
Whitehawk Therapeutics Inc. (NASDAQ:WHWK ) Q4 2024 Results Conference Call March 19, 2025 8:30 AM ET Company Participants Audrey Gross - Head of Corporate Communications Dave Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications David Dornan - Chief Scientific Officer Conference Call Participants Greg Weasner - TD Securities Liang Cheng - Jefferies Operator Ladies and gentlemen, thank you for standing by. Welcome to Whitehawk Therapeutics Fourth Quarter and Full Year 2024 Earnings Call.
Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
2 weeks ago
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision.
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company
Charts implemented using Lightweight Charts™